Capivasertib Patent Expiration
Capivasertib is used for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer with specific genetic alterations after progression on endocrine therapy in the metastatic setting or recurrence within 12 months of adjuvant therapy. It was first introduced by Astrazeneca Pharmaceuticals Lp
Capivasertib Patents
Given below is the list of patents protecting Capivasertib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Truqap | US10039766 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide | Apr 16, 2033 | Astrazeneca |
| Truqap | US9487525 | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide | Apr 16, 2033 | Astrazeneca |
| Truqap | US8101623 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | Mar 10, 2030 | Astrazeneca |
| Truqap | US10059714 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US10654855 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US11760760 | Protein kinase B inhibitors | Oct 10, 2028 | Astrazeneca |
| Truqap | US8809336 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | Oct 25, 2025 | Astrazeneca |
| Truqap | US9006430 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | Oct 25, 2025 | Astrazeneca |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Capivasertib's patents.
Latest Legal Activities on Capivasertib's Patents
Given below is the list recent legal activities going on the following patents of Capivasertib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US10059714 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US8101623 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US8101623 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US10059714 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Apr, 2024 | US9487525 |
| Initial letter Re: PTE Application to regulating agency | 30 Jan, 2024 | US10059714 |
| Initial letter Re: PTE Application to regulating agency | 30 Jan, 2024 | US8101623 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 29 Jan, 2024 | US10059714 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 29 Jan, 2024 | US8101623 |
| Requirement for information sent under 37 CFR 1.750 | 17 Jan, 2024 | US8101623 |
Capivasertib's Family Patents
